Pharmacologic approaches to the treatment of Huntington's disease-Reference-Cited by-同舟云学术

Pharmacologic approaches to the treatment of Huntington's disease

Published:2011-10-13 Issue:1 Volume:27 Page:31-41
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov. Disord.

Author:

Venuto Charles S.,McGarry Andrew,Ma Qing,Kieburtz Karl

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Reference131 articles.

1. Pharmacological management of Huntington's disease: an evidence-based review;Bonelli;Curr Pharm Des,2006

2. A systematic review of the treatment studies in Huntington's disease since 1990;Bonelli;Expert Opin Pharmacother,2007

3. Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions;Scherman;J Neurochem,1986

4. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects;Quinn;J Pharmacol Exp Ther,1959

5. Tetrabenazine has properties of a dopamine receptor antagonist;Login;Ann Neurol,1982

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Translational Approach Using Advanced Therapy Medicinal Products for Huntington's Disease;Current Reviews in Clinical and Experimental Pharmacology;2024-05-23

2. Experiences of young people growing up in a family with Huntington's disease: A meta‐ethnography of qualitative research;Journal of Genetic Counseling;2024-03-12

3. Real-world experience with Deutetrabenazine management in patients with Huntington’s disease using video-based telemedicine;Neurological Sciences;2023-11-17

4. Kaempferol, a potential neuroprotective agent in neurodegenerative diseases: From chemistry to medicine;Biomedicine & Pharmacotherapy;2023-09

5. Gut microbiota dysbiosis and Huntington's disease: Exploring the gut-brain axis and novel microbiota-based interventions;Life Sciences;2023-09